Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
262
resultados
Última actualización
24/03/2026 [06:53:00]
Resultados 175 a 200 de 262
Resumen de: WO2026053150A1
The present disclosure provides pharmaceutical compositions, e.g., drug-containing nanocomposites, nanosuspensions thereof, and lyophilized powders thereof, that increase the apparent water solubility of hydrophobic active pharmaceutical ingredients and provide improved oral bioavailability and pharmacokinetic properties.
Resumen de: WO2026051763A1
Provided are a new gene drug delivery system based on a three-component lipid nanoparticle (LNP), and a preparation method therefor and the use thereof. The three-component LNP is composed of three ingredients: a cationic lipid, a structural lipid and a polymer-conjugated lipid. By means of precise ratio optimization, the three-component LNP maintains an efficient delivery performance while achieving component simplification. Compared with traditional four-component LNPs, the three-component LNP reduces the types of chemical components during preparation, thereby significantly reducing the complexity and cost of the production process, and making the three-component LNP more suitable for large-scale industrial production. In addition, due to the reduction in the types of components, the three-component LNP exhibits improved biocompatibility, reduced potential immunogenicity and toxicity risks, and higher safety.
Resumen de: WO2026051504A1
An optogenetic system promoting the targeted homing of MSCs to a damaged liver, and a preparation method therefor. On the basis that VUR8 exhibits a dimer structure in a natural state and dissociates following UVB irradiation, an optogenetic system comprising light-controlled CXCR4-releasing plasmids which contain UVR8 and CXCR4 sequences and upconversion nanoparticles which can convert NIR having strong tissue penetration capability into UVB is developed, and the optogenetic system is used for implementing the overexpression of CXCR4 only on MSC cells in the liver region so as to promote the targeted homing effect thereof.
Resumen de: WO2026052114A1
A lipid nanoparticle, comprising an ionizable lipid, a steroid compound and a polyethylene glycol-lipid, and not comprising a helper lipid. The ionizable lipid is selected from a compound having a structure represented by formula (I) and/or a pharmaceutically acceptable salt thereof. The three-component lipid nanoparticle not comprising a helper lipid reduces the complexity of the formulation and the difficulty of large-scale production, and further improves the nucleic acid encapsulation efficiency.
Resumen de: WO2026050896A1
Provided is a targeted nano-delivery kit comprising an active ingredient, a targeted guiding agent, and an optional delivery carrier and/or polymer, wherein the targeted guiding agent has the following characteristics: (1) it possesses a recognition group in its chemical structure; (2) the recognition group contains one or more of glycosyl groups of n-valent rhamnose, mannose, and galactose, and derivatives thereof; and (3) the recognition group is linked to an aglycone and/or other glycosyl groups of the targeted guiding agent by means of a covalent bond, where 1 ≤ n ≤ 10. The targeted nano-delivery kit has high drug loading and encapsulation efficiency, exhibits no intrinsic cytotoxicity, and can achieve multiple targeted deliveries. It improves the reliability of the delivery system while providing differentiated pharmacokinetic characteristics, reduces the systemic toxicity of undifferentiated system administration in the prior art, reduces first-pass metabolism, and thereby provides a safer, more reliable, and more effective treatment method.
Resumen de: WO2026050872A1
Provided herein are compositions for delivering a molecular cargo to a lung cell or tissue. The composition may include lipids such as a cationic lipid, a helper lipid, an ionizable lipid, a PEGylated lipid, or cholesterol. Some embodiments include a fusion-associated small transmembrane (FAST) polypeptide. Also provided are methods for using the compositions. The method may include delivering a molecular cargo to a lung cell or tissue.
Resumen de: WO2026050897A1
Provided is a stevioside derivative. The stevioside derivative is a compound represented by general formula Ia, or a salt thereof, or a hydrate thereof, or any mixture of the compound represented by general formula Ia, the salt thereof, and the hydrate thereof. In general formula Ia, R1 and R2 are independent of each other. R1 is selected from hydroxyl or glycosyl, and R2 is selected from n-valent rhamnose, rhamnopyranose, mannose, mannopyranose, galactose, galactopyranose, or combinations thereof, or oligosaccharides formed by means of covalent bonding with other sugars, wherein 1 ≤ n ≤ 10, for example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The derivative or an in-vivo metabolite thereof has balanced hydrophilicity and lipophilicity and a multi-triggerable group and can serve as a delivery carrier and/or targeted guiding agent for an active ingredient. Further provided is a preparation method for the derivative and a use of the derivative.
Resumen de: US20260062688A1
A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.
Resumen de: WO2026052854A1
The disclosure provides nanoparticle lipid compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) a sterol; and (c) a stabilizer. The disclosure provides methods for preparing the lipid nanoparticle compositions and uses of the lipid nanoparticle or the pharmaceutical composition for preventing, treating, or ameliorating conditions or diseases.
Resumen de: WO2026052844A1
P2023-0430-WO 84 ABSTRACT The disclosure provides nanoparticle lipid compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) a sterol; and (c) a stabilizer. The disclosure provides methods for preparing the lipid nanoparticle compositions and uses of the lipid nanoparticle or the pharmaceutical composition for preventing, treating, or ameliorating conditions or diseases.
Resumen de: WO2026052839A1
This invention relates to targeting fusion proteins based on molecules which bind serum proteins, such as serum protein receptors. The invention also relates to amphipathic structures linked to the targeting fusion proteins. The invention also relates to methods of targeting and therapeutic methods using the fusion proteins and/or amphipathic structures.
Resumen de: WO2026052938A1
Pancreatic Disorders The invention relates to a nanoparticle that is suitable for use as a nanoscopic vector for delivering therapeutic agents for use in treating a pancreatic disorder; a pharmaceutical or veterinary composition for use in treating a pancreatic disorder comprising said vectors; and the use of said vectors for treatment of a pancreatic disorder. The invention further relates to a method of treating a pancreatic disorder employing the use of said vectors or pharmaceutical compositions.
Resumen de: WO2026052942A1
The disclosure relates to a lipid nanoparticle (LNP) comprising a plurality of lipids. The plurality of lipids comprises (i) a helper lipid, (ii) a sterol and (iii) a cationic lipid and/or an ionisable lipid. The plurality of lipids does not comprise a PEGylated lipid. The disclosure also provides pharmaceutical compositions and vaccines comprising the LNP, and medical uses thereof. The disclosure also extends to a method of calculating a hydrogen bond potential for a lipid nanoparticle (LNP) formulation.
Resumen de: WO2026052871A1
The invention is based on the finding that fusogenic lipid particles, when coated with serum proteins such as apolipoproteins, retain their fusogenic properties. By coating fusogenic particles with serum proteins such as apolipoproteins, the inventors provide protein-coated fusogenic lipid particles that can be used for targeted drug delivery. The invention pertains to said protein-coated fusogenic lipid particles, their method of manufacturing and therapeutic use, und to methods for targeted delivery of drugs and of the fusogenic lipid particles that rely on the coating of the fusogenic lipid particles with serum proteins. In particular embodiments, the protein-coated fusogenic particles of the invention comprise a polyphenol.
Resumen de: US20260069654A1
A nanoagonist, and a preparation method and use thereof are provided, belonging to the technical field of nanoscale biomedicine. The nanoagonist is formed by self-assembly of a transformable peptide, where the transformable peptide includes a targeted antimicrobial peptide, a functionalized self-assembling peptide, an FcγR recognition peptide, and a lipase-responsive hydrophobic molecule that are coupled in sequence. The functionalized self-assembling peptide can control the FcγR recognition peptide to flip toward a surface of a target pathogen during secondary self-assembly, and the target pathogen is a pathogen targeted and bound by the targeted antimicrobial peptide. The nanoagonist combines externalization of the FcγR recognition peptide that can be guided during the secondary self-assembly with FcγR-mediated endocytosis, and a nanoagonist is developed for the first time that takes into account both pathogen clearance and host immune function repair.
Resumen de: CN121285401A
Novel nanogels comprising one or more bioactive molecules, therapeutic molecules or drugs and amphiphilic molecules and methods of making the same. Biomaterial implants, medical devices or bioprostheses coated with nanogels and methods of producing the same.
Resumen de: AU2024272799A1
The present invention provides a method of producing extracellular vesicles (EVs) comprising incubating or culturing EV producing cells in media. The present invention also provides a population of EVs and compositions comprising the vesicles and methods and uses thereof.
Resumen de: EP4706660A1
The present invention relates to a pharmaceutical composition comprising a telomerase activator and nanoparticles for drug delivery and a composition containing same for the prevention, alleviation, or treatment of hair loss. More specifically, the present invention relates to a composition effective for promoting the regeneration and growth of hair follicles, the composition being a nanoliposome, nano-liposome, nano-silica particle, or nano-bubble composition in which drugs such as the plant extract component TA-65 and a derivative thereof that increase telomerase activity, and the telomerase activating compound GPC and a derivative thereof are encapsulated
Resumen de: EP4707386A1
The present invention provides an artificial viral capsid modified with a compound containing a fluorine atom. The artificial viral capsid is formed by self-assembly of multiple subunits, wherein the subunit comprises a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound, and a divalent linking group that links the β-annulus peptide to the group derived from a fluorine-containing compound; and the divalent linking group is linked to a C-terminus of the β-annulus peptide.
Resumen de: AU2024260092A1
The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.
Resumen de: WO2024226779A1
The present disclosure describes lipid nanoparticle (LNP) compositions and uses thereof, e.g. for treating ocular-related disorders or diseases.
Resumen de: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: WO2024228630A1
The description of the invention discloses a composition comprising 17- AAG and staurosporine for use in the treatment of melanoma, non-small cell lung cancer, pancreatic cancer, mammary gland tumours or gliomas, and a stable polymer-lipid nanoparticle for drug binding and delivery, consisting of a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N - amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2J.
Resumen de: WO2024228632A1
The description of the invention discloses a stable polymer-lipid nanoparticle for drug binding and delivery comprising a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DDPC), cholesterol and the ammonium salt of 1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N -amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2 and a method for producing such particles.
Nº publicación: EP4705275A1 11/03/2026
Solicitante:
ACUITAS THERAPEUTICS INC [CA]
Acuitas Therapeutics, Inc
Resumen de: MX2025013218A
Compounds are provided having the following Structure (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R<sup>1</sup>, R<sup>1</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>2a</sup>, L<sup>2b</sup>, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
BOPI
Sede Electrónica
